Literature DB >> 27256399

Cardiovascular risk after androgen deprivation therapy for prostate cancer: an Asian perspective.

Jeremy Yuen Chun Teoh1, Chi-Fai Ng2.   

Abstract

Androgen deprivation therapy (ADT) plays an important role in managing prostate cancer. However, ADT may result in major cardiovascular events and potentially lead to fatal consequences. Cardiovascular disease is the leading cause of mortality and it is a very important health condition to look into. Asians and Caucasians differ both physiologically and genetically, and they may have display different cardiovascular profiles. In this article, we reviewed the literature focusing on the cardiovascular risk after ADT for prostate cancer in the Asian population. We would discuss about the pathogenesis of ADT leading to cardiovascular events, summarize the findings concerning cardiac and stroke risks after ADT, compare between the different modalities of ADT and also provide genetic basics which are unique to Asians. We hope this article would provide more insights into the cardiovascular risk after ADT for prostate cancer in an Asian perspective.

Entities:  

Keywords:  Androgen deprivation therapy; Asian; Cardiovascular; Myocardial infarction; Prostate cancer; Stroke

Mesh:

Substances:

Year:  2016        PMID: 27256399     DOI: 10.1007/s11255-016-1337-5

Source DB:  PubMed          Journal:  Int Urol Nephrol        ISSN: 0301-1623            Impact factor:   2.370


  41 in total

Review 1.  Future prospects for luteinizing hormone-releasing hormone analogues in prostate cancer treatment.

Authors:  Hideyuki Akaza
Journal:  Pharmacology       Date:  2010-02-03       Impact factor: 2.547

Review 2.  Cardiovascular disease epidemiology in Asia: an overview.

Authors:  Tetsuya Ohira; Hiroyasu Iso
Journal:  Circ J       Date:  2013-06-21       Impact factor: 2.993

3.  Polymorphic repeats in the androgen receptor gene: molecular markers of prostate cancer risk.

Authors:  J L Stanford; J J Just; M Gibbs; K G Wicklund; C L Neal; B A Blumenstein; E A Ostrander
Journal:  Cancer Res       Date:  1997-03-15       Impact factor: 12.701

4.  Absolute and relative risk of cardiovascular disease in men with prostate cancer: results from the Population-Based PCBaSe Sweden.

Authors:  Mieke Van Hemelrijck; Hans Garmo; Lars Holmberg; Erik Ingelsson; Ola Bratt; Anna Bill-Axelson; Mats Lambe; Pär Stattin; Jan Adolfsson
Journal:  J Clin Oncol       Date:  2010-06-21       Impact factor: 44.544

5.  The efficacy and safety of degarelix, a GnRH antagonist: a 12-month, multicentre, randomized, maintenance dose-finding phase II study in Japanese patients with prostate cancer.

Authors:  Seiichiro Ozono; Takeshi Ueda; Senji Hoshi; Akito Yamaguchi; Hideki Maeda; Yuji Fukuyama; Kentaro Takeda; Yasuo Ohashi; Taiji Tsukamoto; Seiji Naito; Hideyuki Akaza
Journal:  Jpn J Clin Oncol       Date:  2012-03-28       Impact factor: 3.019

6.  The heart: a novel gonadotrophin-releasing hormone target.

Authors:  F Dong; D C Skinner; T John Wu; J Ren
Journal:  J Neuroendocrinol       Date:  2011-05       Impact factor: 3.627

7.  Risk of acute myocardial infarction after androgen-deprivation therapy for prostate cancer in a Chinese population.

Authors:  Jeremy Y C Teoh; Samson Y S Chan; Peter K F Chiu; Darren M C Poon; Ho-Yuen Cheung; Simon S M Hou; Chi-Fai Ng
Journal:  BJU Int       Date:  2015-03-07       Impact factor: 5.588

8.  Cardiovascular morbidity associated with gonadotropin releasing hormone agonists and an antagonist.

Authors:  Peter C Albertsen; Laurence Klotz; Bertrand Tombal; James Grady; Tine K Olesen; Jan Nilsson
Journal:  Eur Urol       Date:  2013-11-01       Impact factor: 20.096

9.  Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial.

Authors:  Michel Bolla; Laurence Collette; Léo Blank; Padraig Warde; Jean Bernard Dubois; René-Olivier Mirimanoff; Guy Storme; Jacques Bernier; Abraham Kuten; Cora Sternberg; Johan Mattelaer; José Lopez Torecilla; J Rafael Pfeffer; Carmel Lino Cutajar; Alfredo Zurlo; Marianne Pierart
Journal:  Lancet       Date:  2002-07-13       Impact factor: 79.321

10.  Surgical castration in hormone-refractory metastatic prostate cancer patients can be an alternative for medical castration.

Authors:  Masayoshi Zaitsu; Mariko Yamanoi; Koji Mikami; Yuta Takeshima; Naohiko Okamoto; Sadao Imao; Akiko Tonooka; Takumi Takeuchi
Journal:  Adv Urol       Date:  2011-06-15
View more
  5 in total

1.  Improved cancer-specific free survival and overall free survival in contemporary metastatic prostate cancer patients: a population-based study.

Authors:  Marco Bandini; Raisa S Pompe; Michele Marchioni; Emanuele Zaffuto; Giorgio Gandaglia; Nicola Fossati; Luca Cindolo; Francesco Montorsi; Alberto Briganti; Fred Saad; Pierre I Karakiewicz
Journal:  Int Urol Nephrol       Date:  2017-11-11       Impact factor: 2.370

2.  A cross-sectional study on gut microbiota in prostate cancer patients with prostatectomy or androgen deprivation therapy.

Authors:  Joseph K M Li; Lynn L Wang; Christine Y P Wong; Peter K F Chiu; Jeremy Y C Teoh; Hilda S W Kwok; Steven C H Leung; Sunny H Wong; Stephen K W Tsui; Chi-Fai Ng
Journal:  Prostate Cancer Prostatic Dis       Date:  2021-04-13       Impact factor: 5.455

3.  Cardiovascular toxicities of androgen deprivation therapy in Asian men with localized prostate cancer after curative radiotherapy: a registry-based observational study.

Authors:  Youquan Li; Whee Sze Ong; Ma Than Than Shwe; Nelson Ling Fung Yit; Sheriff Zhan Hong Quek; Eric Pei Ping Pang; Wen Shen Looi; Wen Long Nei; Michael Lian Chek Wang; Melvin Lee Kiang Chua; Terence Wee Kiat Tan; Eu Tiong Chua; Choon Ta Ng; Jeffrey Kit Loong Tuan
Journal:  Cardiooncology       Date:  2022-03-14

4.  Abiraterone and enzalutamide had different adverse effects on the cardiovascular system: a systematic review with pairwise and network meta-analyses.

Authors:  Hsiang Ying Lee; Hsiao-Ling Chen; Jeremy Yuen-Chun Teoh; Tun-Chieh Chen; Shao-Yuan Hao; Hsin-Yi Tsai; Wei-Hsuan Huang; Yung-Shun Juan; Hao-Min Cheng; Hsiu-Mei Chang
Journal:  Prostate Cancer Prostatic Dis       Date:  2020-08-28       Impact factor: 5.554

5.  Risk of ischemic stroke in patients with prostate cancer receiving androgen deprivation therapy in Taiwan.

Authors:  Kuang-Ming Liao; Yaw-Bin Huang; Chung-Yu Chen; Chen-Chun Kuo
Journal:  BMC Cancer       Date:  2019-12-30       Impact factor: 4.430

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.